Over at DiabetesMine #1 health blogger Amy Tenderich has very important post. She and several fellow travelers are appealing to the FDA to strike a balance between safety and progress in allowing new diabetes treatments.

The FDA of course has been beaten to a pulp these last few years because it’s played footsie with the drug industry and ignored several potentially damning studies, with the result that the number of drugs withdrawn from the market has been much higher than in previous years.(Vioxx, Phen-Fen, Baycol, et al).

I’ve always felt that the FDA’s role should not to be a black/white (dangerous/safe) stamp of approval, but instead it should be the honest broker of getting all the data out there. As Amy and her crew point out, some diabetics may be prepared to take a risk of higher long-term cardiac complications in return for a medium term gain from a new medication. Something similar is certainly true in terms of hormone replacement therapy.

Obviously it’s one thing to say that all the information should be
released and then doctors and patients should make an informed choice
on what they want to use. It’s another to actually get pharma companies
to release negative results and for that matter for the FDA to release
all its data. John Abramson’s Overdosed America
shows the very nasty world of that cooperation, including his need to
get a FOIA for the FDA to release information it had about Celebrex
among other drugs.

And on the flip side we know that big Pharma is quite prepared to
push drugs it knows have serious risks and just not disclose them. (Dodgeballl anyone?)

So the FDA has to live in a very imperfect world.

But with the rise of very informed patients, perhaps the new FDA
Commissioner can aim to create a transparent environment in which
everyone in the system (pharma, regulators, doctors and patients) gets
to release and consider all the information about a product and are
then expected to act like responsible grown-ups. It’s an ideal, I know,
but one that someone should stake out. We don’t want to repeat the last
10 years.

1 Response for “Should the FDA relax in the search for new cures?”

  1. Govindan says:

    More transparency would be of real help and FDA should take stringent measures in this direction.

Leave a Reply

THCB ADS




MASTHEAD


Matthew Holt
Founder & Publisher

John Irvine
Executive Editor

Jonathan Halvorson
Editor

Alex Epstein
Director of Digital Media

Munia Mitra, MD
Editor, Business of Healthcare

Laura Montini
Associate Editor

Cindy Williams
Associate Editor

Michael Millenson
Contributing Editor










About Us | Media Guide
© THCB 1995-2012
WRITE FOR US

We're looking for bloggers. Send us your posts.

If you've had a recent experience with the U.S. health care system, either for good or bad, that you want the world to know about, tell us.

Have a good health care story you think we should know about? Send story ideas and tips to tips@thehealthcareblog.com.

ADVERTISE

Want to reach a dedicated audience of healthcare insiders and industry observers? THCB reaches a monthly audience of 100,000 movers and shakers. We reach a total circulation of roughly 450,000. Find out about advertising options here.

Questions on reprints, permissions and syndication to ad_sales@thehealthcareblog.com.

THCB CLASSIFIEDS

Reach a super targeted healthcare audience with your text ad. Target physicians, health plan execs, health IT and other groups with your message.
ad_sales@thehealthcareblog.com
WORK FOR US:

Interested in the intersection of healthcare, technology and business? We're looking for talented interns to work in our San Francisco offices. Get in touch.

Wordpress guru? We're looking for a part time web-developer to help take THCB to the next level. Drop us a line.

SUPPORT:

Let us know about a glitch or a technical problem.

Report spam or abuse here.
SEND US STUFF:

THCB
650 Delancey Street
San Francisco, California 94107

Other stuff you can do:

Subscribe to our RSS feed
Get THCB via Email
Follow us on Twitter
Like us on Facebook